|Company name||Jazz Pharmaceuticals PLC|
|Live stock price||[stckqut]JAZZ[/stckqut]|
|P/E compared to competitors||Good|
|Confident Investor Rating||Good|
|Target stock price (TWCA growth scenario)||$193.92|
|Target stock price (averages with growth)||$188.33|
|Target stock price (averages with no growth)||$188.33|
|Target stock price (manual assumptions)||$185.87|
The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/jazz
Jazz Pharmaceuticals Public Limited Company, incorporated on March 15, 2005, is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD).
Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Jazz Pharmaceuticals PLC as long as the indicators that I describe in my book The Confident Investor are favorable.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.
How was this analysis of Jazz Pharmaceuticals PLC calculated?
For owners of my book, "The Confident Investor" I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
I hope that this makes you a Confident Investor.